Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy
1 other identifier
observational
300
0 countries
N/A
Brief Summary
This study will assess the prevalence and incidence of COVID-19 infection in patients with chronic plaque psoriasis on immunosuppressant therapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2020
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 24, 2020
CompletedFirst Posted
Study publicly available on registry
March 27, 2020
CompletedStudy Start
First participant enrolled
April 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2020
CompletedMarch 27, 2020
March 1, 2020
7 months
March 24, 2020
March 26, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Point prevalence of COVID-19 infection
Baseline up to 6 months
Secondary Outcomes (4)
Incidence of COVID-19 infection
Baseline up to 6 months
Percentage of subjects presenting fever or respiratory symptoms
Baseline up to 6 months
Evaluate the relationship between COVID-19 infection and chronic pharmacological treatments
Baseline up to 6 months
Evaluate the relationship between COVID-19 infection and comorbid medical conditions
Baseline up to 6 months
Study Arms (3)
Group 1
Patients with chronic plaque psoriasis on immunosuppressant therapy
Group 2
Psoriatic patients' partners
Group 3
Patients with atopic dermatitis treated with dupilumab
Interventions
Nasopharyngeal swab for the molecular diagnosis of COVID-19 infection
Eligibility Criteria
This study will enroll patients from the Unit of Dermatology of Azienda Ospedaliera Universitaria di Verona and their partners.
You may qualify if:
- Aged 18 to 75 years old
- Individuals with a clinical diagnosis of moderate-to-severe chronic plaque psoriasis confirmed by the Investigator
- Continuous immunosuppressive therapy (etanercept, adalimumab, infliximab, ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, apremilast, methotrexate, ciclsoporin, acitretin) for the past 3 months
- Is willing and able to sign informed consent to participate
You may not qualify if:
- Patients unwilling to undergo noasopharyngeal swab
- Inability to give informed consent
- Group 2
- Aged 18 to 75 years old
- Partner of a patient with psoriasis enrolled in the study
- Is willing and able to sign informed consent to participate
- Personal history of psoriasis
- Ongoing immunosuppressive therapy
- Patients unwilling to undergo noasopharyngeal swab
- Inability to give informed consent
- Group 3
- Aged 18 to 75 years old
- Individuals with a clinical diagnosis of moderate-to-severe atopic dermatitis confirmed by the Investigator
- Continuous therapy with dupilumab for the past 3 months
- Is willing and able to sign informed consent to participate
- +2 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Biospecimen
Nasopharyngeal swabs
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
March 24, 2020
First Posted
March 27, 2020
Study Start
April 1, 2020
Primary Completion
November 1, 2020
Study Completion
December 1, 2020
Last Updated
March 27, 2020
Record last verified: 2020-03